Literature DB >> 3690809

Intratumoral measurement and plasma pharmacokinetics of intravenously administered melphalan. Report of a patient with plasmacytoma.

S Friberg1, H Ehrsson, S Eksborg, C Carenfeldt.   

Abstract

In a human case of plasmacytoma we studied plasma and tumor concentrations of melphalan given intravenously. Intratumoral concentration of melphalan was similar to plasma concentration 60 min after the end of infusion.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3690809     DOI： 10.1007/bf00262589

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  5 in total

1.  Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine.

Authors:  H Ehrsson; S Eksborg; A Lindfors
Journal:  J Chromatogr       Date:  1986-07-11

2.  Effective treatment of advanced multiple myeloma refractory to alkylating agents.

Authors:  B Barlogie; L Smith; R Alexanian
Journal:  N Engl J Med       Date:  1984-05-24       Impact factor: 91.245

3.  Kinetics of intravenous melphalan.

Authors:  D S Alberts; S Y Chang; H S Chen; T E Moon; T L Evans; R L Furner; K Himmelstein; J F Gross
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

4.  Renal function in the elimination of oral melphalan in patients with multiple myeloma.

Authors:  C G Adair; J M Bridges; Z R Desai
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Distribution and elimination of melphalan in rats and monkeys and distribution in tumors of mice bearing L1210 or P388 leukemias sensitive and resistant to this agent.

Authors:  R K Brown; G Duncan; D L Hill
Journal:  Cancer Treat Rep       Date:  1980 Apr-May
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.